CytomX Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 3/6

Die Gewinne von CytomX Therapeutics sind jährlich um durchschnittlich 26.7% gestiegen, während die Gewinne der Branche Biotechs jährlich um gewachsen um 19.1% gestiegen sind. Die Umsätze sind jährlich um gewachsen 13.7% gestiegen.

Wichtige Informationen

26.7%

Wachstumsrate der Gewinne

34.1%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie17.0%
Wachstumsrate der Einnahmen13.7%
Eigenkapitalrenditen/a
Netto-Marge10.9%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

CytomX: Solving A Critical Problem In The High-Value ADC Space

Sep 15

Aufschlüsselung der Einnahmen und Ausgaben

Wie CytomX Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

NasdaqGS:CTMX Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 24127143288
30 Jun 24120113183
31 Mar 24119173079
31 Dec 23101-13078
30 Sep 2395-103073
30 Jun 2379-423487
31 Mar 2368-713897
31 Dec 2253-9940107
30 Sep 2221-14942129
30 Jun 2227-14343127
31 Mar 2230-13240122
31 Dec 2137-11639114
30 Sep 2166-7239100
30 Jun 2166-643695
31 Mar 2167-613692
31 Dec 2068-6536113
30 Sep 2092-5436127
30 Jun 2085-6336131
31 Mar 2078-7637138
31 Dec 1927-13337132
30 Sep 1961-9937123
30 Jun 1962-9936123
31 Mar 1975-8336118
31 Dec 1860-8534104
30 Sep 1875-523296
30 Jun 1887-393098
31 Mar 1874-5027100
31 Dec 1772-432692
30 Sep 1751-582387
30 Jun 1730-622271
31 Mar 1724-512156
31 Dec 1615-592055
30 Sep 1611-571949
30 Jun 169-571845
31 Mar 168-501637
31 Dec 158-421328
30 Sep 158-361123
30 Jun 158-26818
31 Mar 156-24717
31 Dec 145-35728
31 Dec 131-19511

Qualität der Erträge: CTMX hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: CTMX in der Vergangenheit profitabel geworden.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: CTMX ist in den letzten 5 Jahren profitabel geworden und hat seinen Gewinn um 26.7% pro Jahr gesteigert.

Beschleunigtes Wachstum: CTMX ist im letzten Jahr profitabel geworden, so dass die Wachstumsrate der Gewinne nur schwer mit dem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: CTMX ist im letzten Jahr profitabel geworden, so dass es schwierig ist, das Gewinnwachstum des letzten Jahres mit dem der Branche Biotechs (16.6%) zu vergleichen.


Eigenkapitalrendite

Hohe Eigenkapitalrendite: CTMXDie Verbindlichkeiten des Unternehmens übersteigen seine Vermögenswerte, so dass es schwierig ist, seine Eigenkapitalrendite zu berechnen.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren